This article is more than 5 years old. Information may no longer be current.

Enrollment complete in Zimura trial for geographic atrophy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patient recruitment is complete for a phase 2b clinical trial of Zimura monotherapy for geographic atrophy secondary to dry age-related macular degeneration, Ophthotech announced in a press release.

The randomized, double-masked, sham-controlled, multicenter trial has enrolled 286 patients who will receive various Zimura dosing regimens over 12 months.

Zimura (avacincaptad pegol) is a complement factor C5 inhibitor believed to bind to C5 and stop it from cleaving into terminal fragments C5a and C5b, the release said.

“Recent clinical data together with the preclinical scientific evidence implicating complement in various retinal diseases further invigorates our enthusiasm for the therapeutic potential of Zimura,” Kourous A. Rezaei, MD, Ophthotech chief medical officer, said in the release. “We look forward to initial topline data from this clinical trial, which is expected to be available during the fourth quarter of 2019.”